Recent advances in the understanding of urothelial tumorigenesis

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistic, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistic 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111–122.
   PubMed Web of Science ®Google Scholar
• Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
   PubMed Web of Science ®Google Scholar
• Audenet F, Attalla K, Sfakianos JP. The evolution of bladder cancer genomics: what have we learned and how can we use it? Urol Oncol. 2018;36:313–320.
   PubMed Web of Science ®Google Scholar
• Yousef PG, Gabril MY. An update on the molecular pathology of urinary bladder tumors. Pathol Res Pract. 2018;214:1–6.
   PubMedGoogle Scholar
• Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci. 2020;8:15.
   Google Scholar
• Suzuki S, Cohen SM, Arnold LL, et al. Orally administered nicotine effects on rat urinary bladder proliferation and carcinogenesis. Toxicology. 2018;398-399:31–40.
   PubMed Web of Science ®Google Scholar
• Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxin exposure in long-term E-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med. 2017;166:390–400.
   PubMed Web of Science ®Google Scholar
• Ji H, Jin Z. Analysis of six aromatic amines in the mainstream smoke of tobacco products. Anal Bioanal Chem. 2022;414:4227–4234.
   PubMedGoogle Scholar
• Tang MS, Wu X-R, Lee H-W, et al. Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. Proc Natl Acad Sci, USA. 2019;116:21727–21731.
   PubMed Web of Science ®Google Scholar
• Wei M, Wanibuchi H, Yamamoto S, et al. Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis. 1999;20:1873–1876.
   PubMed Web of Science ®Google Scholar
• Waalkes MP, Liu J, Ward JM, et al. Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. Toxicol Appl Pharmacol. 2006;215:295–305.
   PubMed Web of Science ®Google Scholar
• Kurttio P, Pukkala E, Kahelin H, et al. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect. 1999;107:705–710.
   PubMed Web of Science ®Google Scholar
• Shukla V, Chandrasekaran B, Tyagi A, et al. A comprehensive transcriptomic analysis of arsenic-induced bladder carcinogenesis. Cells. 2022;11:2435.
   PubMedGoogle Scholar
• Almutairy B, Fu Y, Bi Z, et al. Arsenic activates STAT3 signaling during the transformation of the human bronchial epithelial cells. Toxicol Appl Pharmacol. 2022;436:115584.
   Google Scholar
• Phillipsen S, Suske G. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res. 1999;27:2991–3000.
   PubMedGoogle Scholar
• Chen X, Wang P, Ou T, et al. KLF16 downregulates the expression of tumor suppressor gene TGFBR3 to promote bladder cancer proliferation and migration. Cancer Manag Res. 2022;14:465–477.
   PubMed Web of Science ®Google Scholar
• Sekine H, Motohashi H. Roles of CNC transcription factors NRF1 and NRF2 in cancer. Cancers (Basel). 2021;13:541.
   PubMedGoogle Scholar
• Qian J, Huang C, Zhu Z, et al. NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer. Carcinogenesis. 2022;43:457–468.
   PubMedGoogle Scholar
• Ide H, Miyamoto H. The role of steroid hormone receptors in urothelial tumorigenesis. Cancers (Basel). 2020;12:2155.
   PubMedGoogle Scholar
• Miyamoto H, Yang Z, Chen Y-T, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99:558–568.
   PubMed Web of Science ®Google Scholar
• Kawahara T, Inoue S, Kashiwagi E, et al. Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis. Am J Cancer Res. 2017;7:2041–2050.
   PubMedGoogle Scholar
• Izumi K, Taguri M, Miyamoto H, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget. 2014;5:12665–12674.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Goto T, Jiang G, et al. 5α-Reductase inhibitors do not prevent the development and progression of urothelial cancer: in vitro evidence. Bladder Cancer. 2020;6:481–488.
   Google Scholar
• Inoue S, Ide H, Mizushima T, et al. ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor. Am J Cancer Res. 2018;8:2325–2336.
   PubMedGoogle Scholar
• Nagata Y, Kawahara T, Goto T, et al. Effects of α1-adrenergic receptor antagonists on the development and progression of urothelial cancer. Am J Cancer Res. 2020;10:4386–4398.
   PubMedGoogle Scholar
• C-C L, Lin M-Y, Chen S-Y, et al. The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder. BMC Complement Altern Med. 2013;13:44.
   PubMedGoogle Scholar
• Ikarashi N, Hoshino M, Ono T, et al. A mechanism by which ergosterol inhibits the promotion of bladder carcinogenesis in rats. Biomedicines. 2020;8:180.
   PubMedGoogle Scholar
• Sethakorn N, O’Donnell PH. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma. BJU Int. 2016;118:681–691.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–348.
   PubMed Web of Science ®Google Scholar
• Goto T, Miyamoto H. Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements? Exp Rev Anticancer Ther. 2020;20:229–231.
   PubMed Web of Science ®Google Scholar
• di Martino E, Alder O, Hurst CD, et al. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer. Sci Rep. 2019;9:5740.
   PubMedGoogle Scholar
• Zhao B, Zhao Y, Jiang H-P, et al. The role of insulin-like growth factor axis in bladder cancer: a systematic review and meta analysis. Int J Clin Exp Med. 2016;9:784–793.
   Google Scholar
• Tsai C-W, Chang W-S, Xu Y, et al. Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk. Mol Carcinog. 2021;60:726–733.
   PubMedGoogle Scholar
• Huang W, Li Y, Zhang C, et al. IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signaling pathway in human bladder cancer. J Cell Mol Med. 2020;24:13949–13960.
   PubMed Web of Science ®Google Scholar
• Solomon JP, Hansel DE. The emerging molecular landscape of urothelial cancer. Surg Pathol Clin. 2016;9:391–404.
   PubMedGoogle Scholar
• Ciccarese C, Massari F, Blanca A, et al. Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opin Ther Targets. 2017;21:401–414.
   PubMed Web of Science ®Google Scholar
• Masuda N, Murakami K, Kita Y, et al. Trp53 mutation in keratin 5 (Krt5)-expressing basal cells facilitates the development of basal squamous-like invasive bladder cancer in the chemical carcinogenesis of mouse bladder. Am J Pathol. 2020;190:1752–1762.
   PubMedGoogle Scholar
• Arnoff TE, El-Deiry WS. CDKN1A/p21WAF1, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies. Am J Cancer Res. 2021;11:5452–5471.
   PubMedGoogle Scholar
• Isono M, Okubo K, Asano T, et al. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells. Sci Rep. 2021;11:10181.
   PubMedGoogle Scholar
• S-J F, Shen S-L, S-Q L, et al. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma. BMC Cancer. 2018;18:815.
   PubMedGoogle Scholar
• Yamamoto Y, Matsuyama H, Chochi Y, et al. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet. 2007;174:42–47.
   PubMedGoogle Scholar
• Jiang N, Liao Y, Wang M, et al. BUB1 drives the occurrence and development of bladder cancer by mediating the STAT3 signaling pathway. J Exp Clin Cancer Res. 2021;40:378.
   PubMedGoogle Scholar
• Wendler F, Purice T-M, Simon T, et al. The LMTK-family of kinases: emerging important players in cell physiology and pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2021;1867:165372.
   PubMedGoogle Scholar
• Jiang T, Lu X, Yang F, et al. LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway. FEBS Open Bio. 2020;10:2107–2121.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761–773.
   PubMed Web of Science ®Google Scholar
• Hatogai K, Sweis RF. The tumor microenvironment of bladder cancer. Adv Exp Med Biol. 2020;1296:275–290.
   PubMedGoogle Scholar
• Du Y, Sui Y, Cao J, et al. Dynamic changes in myofibroblasts affect the carcinogenesis and prognosis of bladder cancer associated with tumor microenvironment remodeling. Front Cell Dev Biol. 2022;10:833578.
   PubMedGoogle Scholar
• Du Y, Cao J, Jiang X, et al. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression. Cancer Cell Int. 2021;21:613.
   PubMedGoogle Scholar
• Luo W, Wang J, Xu W, et al. LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. Cell Death Dis. 2021;12:1043.
   PubMed Web of Science ®Google Scholar
• Huang Z, Gao H, Qing L, et al. A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/β-catenin signaling pathway. PeerJ. 2022;10:e13220.
   PubMedGoogle Scholar
• Li Y, Zheng Y, Izumi K, et al. Androgen activates β-catenin signaling in bladder cancer cells. Endocr Relat Cancer. 2013;20:293–304.
   PubMed Web of Science ®Google Scholar
• Lin C, Yin Y, Stemler K, et al. Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res. 2013;73:5914–5925.
   PubMed Web of Science ®Google Scholar
• Phé V, Cussenot O, Rouprêt M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 2009;104:896–901.
   PubMed Web of Science ®Google Scholar
• Luo J, Xu J, Ou L, et al. Role of hypermethylated-lncRnas in the prognosis of bladder cancer patients. J Int Med Res. 2021;49:1–12.
   Google Scholar
• Liang Z, Guo W, Fang S, et al. CircRNAs: emerging bladder cancer biomarkers and targets. Front Oncol. 2021;10:606485.
   PubMedGoogle Scholar
• Zhang X, Liu X, Jing Z, et al. The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer. Cancer Gene Ther. 2020;27:189–202.
   PubMedGoogle Scholar
• Inoue S, Ide H, Mizushima T, et al. Nuclear factor-κB promotes urothelial tumorigenesis and cancer progression via cooperation with androgen receptor signaling. Mol Cancer Ther. 2018;17:1303–1314.
   PubMed Web of Science ®Google Scholar
• Chen Q, Yin Q, Mao Y, et al. Has_circ_0068307 mediates bladder cancer stem cell-like properties via miR-147/c-Myc axis regulation. Cancer Cell Int. 2020;20:151.
   PubMedGoogle Scholar
• Wei Z, Xu J, Li W, et al. SMARCC1 enters the nucleus via KPNA2 and plays an oncogenic role in bladder cancer. Front Mol Biosci. 2022;9:902220.
   PubMedGoogle Scholar
• Tang F, Yu H, Wang X, et al. NCAPG promotes tumorigenesis of bladder cancer through NF-κB signaling pathway. Biochem Biophys Res Commun. 2022;622:101–107.
   PubMedGoogle Scholar
• Xie H, Li J, Ying Y, et al. METTL3/YTHDF2 m6A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRnas in bladder cancer. J Cell Mol Med. 2020;24:4092–4104.
   PubMed Web of Science ®Google Scholar
• S-R H, Lee Y-C, Ittmann MM, et al. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021;520:344–360. .
   PubMedGoogle Scholar
• Zheng Y, Izumi K, Yao JL, et al. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer. 2011;15:451–464.
   Google Scholar
• Albarrán V, Rosero DI, Chamorro J, et al. Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates. Int J Mol Sci. 2022;23:12659.
   PubMedGoogle Scholar
• Li Y, Ishiguro H, Kawahara T, et al. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014;4:461–473.
   PubMed Web of Science ®Google Scholar
• Afsharimoghaddam A, Soleimani M, Lashay A, et al. Controversial roles played by toll like receptor 4 in urinary bladder cancer; a systematic review. Life Sci. 2016;158:31–36.
   PubMedGoogle Scholar
• Reis LO, Salustiano ACC, Capibaribe DM, et al. Castration immunoregulates toll-like receptor-4 in male bladder cancer. Int Urol Nephrol. 2022;54:2845–2853.
   PubMedGoogle Scholar
• Xiao J-F, Caliri AW, Duex JE, et al. Targetable pathways in advanced bladder cancer: fGFR signaling. Cancers (Basel). 2021;13:4891.
   PubMedGoogle Scholar
• Izumi K, Ito Y, Miyamoto H, et al. Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget. 2016;7:14153–14160.
   PubMed Web of Science ®Google Scholar
• Kawahara T, Ide H, Kashiwagi E, et al. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. Am J Cancer Res. 2015;5:2959–2968.
   PubMed Web of Science ®Google Scholar
• Shiota M, Takeuchi A, Yokomizo A, et al. Androgen receptor signalingregulates cell growth and vulnerability to doxorubicin in bladder cancer. J Urol. 2012;188:276–286.
   PubMed Web of Science ®Google Scholar
• Kashiwagi E, Ide H, Inoue S, et al. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget. 2016;7:49169–49179.
   PubMed Web of Science ®Google Scholar
• Mizushima T, Jiang G, Kawahara T, et al. Androgen receptor signaling reduces the efficacy of bacillus Calmette-Guérin therapy for bladder cancer. Mol Cancer Ther. 2020;19:1930–1942.
   PubMedGoogle Scholar
• Ide H, Miyamoto H. Sex hormone receptor signaling in bladder cancer: a potential target for enhancing the efficacy of conventional non-surgical therapy. Cells. 2021;10:1169.
   PubMedGoogle Scholar
• Kakiuchi-Kiyota S, Schutten MM, Zhong Y, et al. Safety considerations in the development of Hippo pathway inhibitors in cancers. Front Cell Dev Biol. 2019;7:156.
   PubMedGoogle Scholar
• Osher E, Macaulay VM. Therapeutic targeting of the IGF axis. Cells. 2019;8:895.
   PubMed Web of Science ®Google Scholar
• Liu R, Wettersten HI, Park S-H, et al. Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem. 2013;5:991–994.
   PubMedGoogle Scholar
• Amalina I, Bennett A, Whalley H, et al. Inhibitors of the Bub1 spindle assembly checkpoint kinase: synthesis of Bay-320 and comparison with 20H-BNPP1. R Soc Open Sci. 2021;8:210854.
   PubMedGoogle Scholar
• Zhang Y, Liang X, Bao X, et al. Toll-like receptor 4 (TLR4) inhibitors: current research and prospective. Eur J Med Chem. 2022;235:114291.
   PubMed Web of Science ®Google Scholar
• Lokeshwar SD, Lopez M, Sarcan S, et al. Molecular oncology of bladder cancer from inception to perspective. Cancers (Basel). 2022;14:2578.
   PubMedGoogle Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556.e25.
   PubMed Web of Science ®Google Scholar
• Song YP, McWilliam A, Hoskin PJ, et al. Organ preservation in bladder cancer: an opportunity for truly personalized treatment. Nat Rev Urol. 2019;16:511–522.
   PubMedGoogle Scholar